0001753926-24-000584.txt : 20240321 0001753926-24-000584.hdr.sgml : 20240321 20240321090052 ACCESSION NUMBER: 0001753926-24-000584 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240321 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chromocell Therapeutics Corp CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 863335449 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 24769660 BUSINESS ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 BUSINESS PHONE: 9176446313 MAIL ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 8-K 1 g084141_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 21, 2024

Chromocell Therapeutics Corporation
(Exact name of registrant as specified in its charter)

Delaware		001-41964		86-3335449
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4400 Route 9 South, Suite 1000 Freehold, NJ		07728
(Address of registrant’s principal executive office)		(Zip code)

Registrant’s telephone number, including area code: 732-514-2636

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CHRO		The NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On March 21, 2024, the Company issued a press release announcing the launch of its eye pain treatment program with the hiring of Dr. Simon Chandler, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in such exhibit shall not be deemed filed for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of Chromocell Therapeutics Corporation, dated March 21, 2024.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 21, 2024	CHROMOCELL THERAPEUTICS CORPORATION

	By:	/s/ Francis Knuettel II
		Name: Francis Knuettel II Title: Chief Executive Officer and Chief Financial Officer

EX-99.1 2 g084141_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

New Program Targets Estimated $2.5 Billion Eye Pain Market

Freehold, New Jersey — March 21, 2024 — Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.

The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications. Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae. Chronic eye pain indications include autoimmune diseases, dry eye and neuropathic etiologies. Chromocell’s platform uniquely targets the NaV1.7 channels on the cornea with the ability to treat all eye pain indications.

“The launch of our eye pain treatment program represents a significant milestone for the Company. Eye pain indications are currently under-served for treatment options, and we believe, based on the data from our programs which address various forms of systemic chronic pain using the same mechanism, that targeting NaV1.7 sodium channels in the cornea represents a viable, safe and effective treatment paradigm for eye pain,” said Frank Knuettel, CEO of Chromocell. “Moreover, the market opportunity in these under-served markets is considerable. As an example, we estimate that there are roughly 5 million corneal abrasions annually in the United States, representing an estimated market opportunity of roughly $2.5 billion.

I welcome Dr. Chandler and look forward to working with him as he guides this program towards providing much needed, effective treatment options to sufferers of eye pain in the United States and globally,” he added.

Dr. Chandler is well suited to manage the program, with over 30 years of experience in managing ophthalmic drug development programs. He has a Ph.D in Epigenetics and had a post-doctoral position at the NIH studying molecular embryology. With posts at Santen, ISTA, B&L, Allergan and Vyluma, he has successfully developed several drugs in the areas of glaucoma, and post-surgical eye pain, such as Durysta for Glaucoma and Bromday in pain and inflammation post cataract surgery.

About Chromocell Therapeutics Corp.

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company’s portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the Company intends to explore these and other compounds for the treatment of additional pain indications. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media.

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the Company’s belief that its portfolio of therapeutics will be suitable for an array of eye pain indications, (ii) the Company’s belief that the market opportunity in under-served markets is considerable and (iii) the Company's intent to explore certain compounds for the treatment of pain indications. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to (i) the Company expending its limited resources to pursue a compound or indication and failing to capitalize on different compounds or indications that may be more profitable or for which there is a greater likelihood of success and the Company potentially not being successful in discovering, developing and commercializing additional compounds, (ii) the Company needing to establish its market development capabilities to commercialize its products with the failure to do so potentially resulting in an inability to generate any revenue, (iii) the Company facing significant competition and its competitors potentially achieving regulatory approval before the Company or developing therapies that are more advanced or effective than the Company’s, which may adversely affect the Company’s financial condition, (iv) the Company’s ability to obtain and maintain adequate U.S. and foreign patent protection for its compounds, the Company facing litigation or administrative proceedings by a third-party over its patents, changes in U.S. or foreign patent law or interpretation thereof diminishing the value of its patents, and the Company’s ability to protect the confidentiality of its trade secrets, (v) third-parties instituting patent litigation against the Company in the U.S. or a foreign jurisdiction asserting that CC8464 and/or additional lead compounds infringe its patent rights, the outcome of which would be uncertain and could have a material adverse effect on the success of the Company’s business, (vi) there being no guarantee that the results from prior clinical and preclinical studies will be indicative of the Company’s ability to complete studies or the results to be obtained in the current or future studies and clinical trials and (vii) the Company’s ability to retain key employees and scientific advisors and to attract, retain and motivate qualified personnel. These and other risks and uncertainties are described more fully in the section captioned “Risk Factors” in the Company’s Registration Statement on Form S-1 (SEC File No. 333-269188). Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Chromocell Media and Investor Inquires:

LR Advisors LLC.

Jason Assad

678-570-6791

Jason@Chromocell.com

EX-101.SCH 3 chro-20240321.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 chro-20240321_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 chro-20240321_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 image_003.jpg GRAPHIC begin 644 image_003.jpg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htm IDEA: XBRL DOCUMENT

Cover	Mar. 21, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 21, 2024
Entity File Number	001-41964
Entity Registrant Name	Chromocell Therapeutics Corporation
Entity Central Index Key	0001919246
Entity Tax Identification Number	86-3335449
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4400 Route 9 South
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Freehold
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07728
City Area Code	732
Local Phone Number	514-2636
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CHRO
Security Exchange Name	NYSEAMER
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://chromocell.com/role/Cover Cover Cover 1 false false All Reports Book All Reports chro-20240321.xsd chro-20240321_lab.xml chro-20240321_pre.xml g084141_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "g084141_8k.htm": { "nsprefix": "CHRO", "nsuri": "http://chromocell.com/20240321", "dts": { "schema": { "local": [ "chro-20240321.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "chro-20240321_lab.xml" ] }, "presentationLink": { "local": [ "chro-20240321_pre.xml" ] }, "inline": { "local": [ "g084141_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://chromocell.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "g084141_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "g084141_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://chromocell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001753926-24-000584-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001753926-24-000584-xbrl.zip M4$L#!!0 ( !E(=5CS3K73*P, .D+ 1 8VAR;RTR,#(T,#,R,2YX M],_T'UNS'&35,()-.02<,TMY)K\](1]IIH(DN.)'/Y^TJ^ M!3 0H*V?Y-USSNY*N[+;1Y.(HA$(23CK6&ZM;B%@/@\(&W:LNQO[VTVWU[/0 MT>''#T@_[4^VC4X)T*"%3KAO]UC(#] ECJ"%O@,#@147!^@>T\18^"FA(%"7 M1S$%!=J116JAO5K#'2#;WD#W'EC Q5V_5^H^*Q7+EN.,Q^,:XR,\YN)%UGP> M;29XH[!*9*E6G]3S9S/Z!9%^26Z^?H[Y_J1/'H? OB9G3]Z+?, /ES"X5N/X MV&L\T>-1(]X/@Y?7VVF/[NV]GEU.?TW@I!O5?U[\R$*VI?\,$4;Z,)CL6*:^ MO+RQ5^-BZ#3J===YO#B_27%6!FQ-*&$OR^!NL]ET4F\!K2 G T$+:<\Q[@&6 M4"IK+UF#)TPJS/PY?*!*PBQXS\F<P]6S12$"IDZYB$X@Q G5J;PFF)*00& AA<40E&DS&6,?WM4KNA4S MQG53Z\G*+<86QT1W;6G0)G/*+<$IW.KTD5GHJ5H5Q+B=+M=W@X5(T+&RY8Q< M(1A 2!A)@^=SY"+;3$UB2M7+E-EV%L%5I41"<,4.TW4L0&IZ6M2Y-N3\'+*> MZV/J)W0GZEM^ZYBYO=C*RAX7X]2'$*5CV#(-T[$D,1>AE=N>!80=RVR[79SH M;UUV33=4 3$1UHQA>D:+.Y4'+B2P\"LJE6M"B_ 8A"*ZJV?N@BQUH@S]>B8, M,G&DA9Q_6#G%@VTKUQ2@_['D;,+GFU,MMNP/;<@1*.D3"B#5N?H^>N3N<] M9OHN=VH"GR=,B>DVC3!+*5YV.XVW/X#-#J+ 9X=@?@IV#;M#%U2#+VN!MI.I MZ>4?4$L#!!0 ( !E(=5AQ2Y5M_0H ("& 5 8VAR;RTR,#(T,#,R M,5]L86(N>&ULS9U=;^.X%8;O"_0_<-V;%AC'$P(7&XP'U?B,LYN+K_;RJ]S'+GM.SR>3U]?6(\1?\RL53>A3Q MS; *%QG.MFE5V\?=Q_)/$?Z))NSI3/VUPBE!\GBQ]&R7)NA$]D@T>)TP=MXB,=)2JQ19W?'IZ.LE+M;2EW*T$U?LXF6@[ M5/CZ?CD^&B7QB-]\/,C M*#@E]^0!Y0#;-=IHZXR:.+:[!T1"8\OV?M[,OOCLC^AP;4XYTW M8=\1/\2Y/])RG"?O.]*UR/^+[:QM^,RY7 Q2K-!(XR75/>C/.1I7QB6E+*"Z%]81'U-*Y4 M3"(NIZ;G;$R+PUB$/PB^L>ZV;#6W%/Y!5U5\<5CD+@"C#9D@*=^*B+RI5^IN MH:-4.MI0J5!+*L+&7Q>C'W(-^EVK_O-IKF+R2-1/*LEO-=[6C(G'>ZQ62K[VN:L!!H&X-)J&D]#>SW9)VH MJ4594.>W1&WL&,8 O>NAO].V.1=8Q4% ,\0A.%O4@U 5Y8FC"\:VF-Z39RZZ M\&G*7%-C,VG"4M<$Q8C%&(A&H46%V!,1OV[E&3L1=-\+14OIF@O JHF&(0N* M#KLW$)!*[I>1I< L3=0 U@M)6^K\= ,PVSKU,'1!<0*8@T])*KU?4A:/A%)U M/P"S_@'%)G9-"VS8Y*6M#(H8T![(3!Z!RI!PL+E\4:MSN4P:V-B:WB<\+=M= M_%3B8!$R'0ZD* ]#*LX32;7;$#T,M92NZ0&LFMP8LJ"(L7L#62GD*-?[A^22 MQ8,0J71^ #%LVO$H10'"T736AX94^P3C*DDC3 LO5W);VM$\B]8U(*!=$Y*6 M,"A0('<@+$6 9B8/\0K,OP@6PW"I*?W TK)J1Z62!0B*Z:T/$Z7W LEL*T3# M-3SCP%)G-V5[S%;W9P%=$*#TF&O=M2WD#5 \S4"7+$NRO7J>[F:[61%A:5Q; MXHH-R)QFPBP/@@7 E,E (4-*APJAEY[7=PE8IAYB!)MCRMP28#?9I*"I"8@$ MJS& AH,V?Z;4"Q$S.3()3.P+@3R0:+_2*)>J:*MM M&I#1)ANF*B X &L ':4:+>8SGS/)$N_FL00U M>4B*Y\%[* 'U;F'IL=UD!A 'A$ZW0X @&82:43Y!FK.(BV=>>]QAQK=R -S/ M> RO4'JBW$(UJ E-M#I# @)LB$\ LT;HA^*9%,35>SQY!4C5X(6XBSB6!RHM M_[E.&#D&VV_5NJ6KPVZ3*8LP())@=P _I?*#_H!4#+IEH4 S?4-3I_ZAF0Z% M9AHT--/W0+-\Y8% <_*&II[XA^9D*#0G04-S\BYH9,=['6MF\N.M6/)7V\/9 MH-(+,FVK5F .LO!P:7GK@T4%J/6,"O&)2;ZPNA5W@K\D+(*7S)#<"S" :2LU MAC8\=.P&^_BI%L0ZSNM84RS*>[\D6N9GE&F:M \QA28\2)K&>@>70NT3B3N> M9IC^.WGN/!&WB[W@835LA:2A# \5F[T^8(H8)(-\G%B7N*H;&M97R8QR=Z\ M6VP=7@&N%08!@<8WFRTK[_+8GAL$=*YZ MN=.F[G&K*(C>[W)FDE!J45/L&(L%ITF49 E;_R)//D6";:VRB5P! 1O4-+05 M0: VC(Y. B15CJ&X$X0!2&1'9&_!*@2"XG;AP?K;-\E=@5%OV$-!ZP, I)> M>R8L,F $((- ^ U-*'B!-DLA>J(M G6PL2 M;>7\N#^>KI9)1FTGEVV)LSD),%?-2$9Y$&P IDP6\C+$']#Q]*^KOR$=Y;C[ M;_A28)4\=K'?K#@%LD]95:X@Z+"H.;!(@D !]F72<,-1*46%UD=VJH992W., MM+W^CKST-^9>[Z%&:(L +"7:9ZZ'?9M(<_NN:(!#H M,-8Z*2FE2&M]O)!PF++6_8N M;=%P+IG$; .<1&P'KH(6'M;!.C=%BE"Y+AT MNZ+)&@/)"3O5KJ'HL&SR89$&A0KL#QPSJA!TB'&=T3)/<:;2\XM-OO\K^<'2 M2D#G+*=EE\TJJ:5-% 0C7@/;"\E= MOU399=I\F]*F#0BA3H/@^Y-5C$H5@S53WE+&B)E<:JUYQU/BALI]XIB6Q7;N MF$H2$!XV7QT99 326B\L+#:8TL_;-&$DA26+C<$+&6T]M/@K]FCV5^5K!M@-HM&YV6FXQ8I0&QTN4/8$:'H")&I]3U M \_ND%"\R+((M]0B=8P-:-9@IJ4+"1C(7(L62B)UO>6&9VC)T=>4H.R1H,OR M9^CJF>"+>GS]TD@4J17N(U1(Y7QA:#QL*XI@B"$= 6M"RN_U: G]QYVQ5-HBO*,7R5I:%Q MG#&O;<](EG<0!$1 VQ64(B\7HESII?\_8_8DML]9M+\3/")$/6655J-5W_6W M@=%NF7E3DYHT#0H-B+.W^ 4(/%2!:G5\J,U8/B_FJ8?&538W'CTM'K$\@+?; M+%4SJ#0&7P7O#')\>V% XR;#!T1 :$WP"9TPR&/1'GH!U0$HUJTI_.S]) % MD,2?]_?D@0CUWL&2[++/JEJ%X! M6JEGQ,HJT.^J$I378OO]\OJF:_E);M:;Y%\KG!*YY;]02P,$% @ &4AU M6$,YNB57!P V5< !4 !C:')O+3(P,C0P,S(Q7W!R92YX;6S-G%USVC@4 MAN]W9O^#E[TF!.A^)$VVD]#089HVV9"VNWO3$;8 362)D>0 _WXE&U,^+/GD MQB>Y2(AY]?$^QY9];,D7[U8ICYZITDR*RU;WY+0541'+A(G99>O+N'TU'HQ& MK4@;(A+"I:"7+2%;[_[Z^:?(_ES\TFY'0T9YF36*:P"L>&F$QO:SM=G6Y^BN(7G(FG<_=K0C2- M+"^ASU>:7;9UHLY>RPM%-14F-WMK-^P5 MH2MC=RB:E!6Y]N%],\PX^6:'Z49MMW=EJ6W-?BR4FZZ4G>$RWFN?NRC( [/E M'IVSUC0^F/; M.$]M9'UT-B2DIZ.[H&P3S="\LNTGK@]#3F;5. \D0)Y=#*"5;K"(OJ>P\T!ES_75=<:=8O*N\(6'^.R/*4,77$-)'8B#LWS!A>QPB\7Y41&CF M^$" 'ZN!Q']'O?#P>$1"/I[;2V*7QA$!VLNK]$#L?V!B]_M\!>!OGMWYW9Y: MX.QWB@#Q__E:\!^Y18K /55,)O:4K@#LC\1 ZF>8U#T.47G?B 1*>RL%YS_X ML _L(:$>,AT37O1H:+?I,.X*.10Y2LY9:Q,5^[^4*##T'3$4.4H:6F.Q8>"# M3*F]S@1'%;\:BAPE :TSV3#S&V&86;O[_I^S=/+CQND^ZV,5E#%*TNDSA<*V MO-,@C'N<$>)[J(0R1LDU0^90. ^L'T7X2"1T]9&N0Z"/I%#2*#EFT!X*ZGO% M4J+68Q;7#QK'6BALE,PR;!"%]B-9C1+KBDU9\4"P'KJW")0]2EH)LHL2@I&( MI5K(G=O% YG9XW$]D$EP2*\I" T'2K[Y NLH0;E*$HM+;_[<,D&[H5!4RL'/ MB/ "$+#Y2K#W7H:]!\>.DH?6VGPEV/LOP]Z'8T?)16MM8F(?V(]WZE$N/4^@ MO6(H6- MF*Y6F\/D?"^U(?P_MJB[DJS60YDC)JXAHTW?8"SB[FY:^*82'4B@?%%RU4H[ M32-U$5:4^'???044*$H"6F6F89ZWTCW[F$L1O!][K()R1WUC#A.\5=9&F]K([G\?EUAJHN^G4-_*&]%#B M*+E>O5%<\B.M,ZI>RK^B%#0**&D?U'33XPR-,SOLK;N]R:-;,>,998Y44-8H M*9_/5,-L/\M'1=QZO?$ZG4CN7QY2*8021DGP M8:AKS7CVJ\!Q(H6)3,KM(. MTIAPLXKG1,RH?_9"M1(*&"73"YE#&WMGH+%W]L*Q%R7C\YE"8EO,#;='U-V$ MLQGQKR0+%@"OL\$D'K#:]/J]?,F/6\FMTKP?0_NA&KM'"@6.LT0R9*]IU%G" M#$V*+@V9("*V*=5V79LG.Z\O!0T SAI*H&F4V_O?*.(M H(#Y#K+&+$H*ODF>6DLHG@BK/,>"10I$C/COTV,.9>UE,:MZ>>XI7 M=H2(^TI P2,^1 R;19J?9JCK,WNF[XDAFQZ&^/M*0/DC/E ,FT6;/Z\&]L0S MD^%GY@="*&W$J;"5UE @CU/"^76FF: Z.+8<"*&0$>>\5EI#@7R34C6S@]H' M)9=FOEG;&8+M*0"%CCBS-6@5!_[JQSKR8OU;D'R%&OQV D3L7I-8K]V(8S>1 MHCB3BX0H#_60'LH==6&EWVC#Y._,G*K=ZZ>\,R.;MX4F/=27@D8!)5V%FL8Y MM^ZLY ^>6O=T4-Z(B6F5,9PU4]F$LWC()0E>E^_)H'P1L] *6RAXKXEX4MG" MQ.M[)6-*W>,3O3W: D1L )H2!#STQ>AP+E=(-/4+2:2\=-X;DWKN\SD;S"U M_0O>- B6@X8&*0K@I?% &*0^.# M^D8A,(:*,%UTCGS=V@WN';7%-^Z7>P^KW?(_4$L#!!0 ( !E(=5AYSX \ M@Q$ &V . 9S X-#$T,5\X:RYH=&WM'>];XCCS.W]%7NZ].WT>^=&" M*.CR/BSBRJVK'K"WN_?%)[2!=BUM-TT5]J]_9](66B@KNJAXQSUWIY!D9C*9 MF/J( E M1$C[N:*:4RLQ(#F/:0E \#D_=&[OA7.8*RD1G(7%23:Z+8,:J2E4M5U8'6WD+3#ZY5JY# MBQ# AZ\> $*][AJ4,^]:O9;V+X#AR>\> .8$*;D*0946"%H&N^_H$^*)B<7> M9 <@=36B%%U!>N8(>ERP.])Q1M3>"[[8 _S<'*!PZ^9M-$PW/=>BDQJQ'9MA MFSFNH: R#M(O/YBZSFQ4!?P$O2[\$<#1 C$?BP[:BH9W.4 )R15+.= ?8L,D M 38S:XF%SQ)3?Y,UQ[>Y4J6:K4LQ."XDP#X:4:I%+/UF92D82W$9XLT M@*%C'+9>YLEV-*?X/,0$G>2"U\*9RTG,S3RT35%/)FQ4.'S6^N"YSY.7 C.&\839SLBT[\%Y+S_FD:: MC9KCTY]G8ZAZ,TT+5#ZT=L<%&%O/9#+';F0<1Y0/3;M&P'0<%]QZO&E5N+*O9WYG 1G9^F^_*)7B MT7$! ;X&>H_[]8\7[5[K)-/M-7JM[G&?@X7LMIH?.^U>N]4EC8L3TOKX8J=7G8^ M9 *(:(?0?:D63Z5_ELN=.)J/>SWZP=?:U'><>9'?)\:G[^QCL5C] [:P1^WS M<1RQ[;T*.GJ8>S^_KT]YNQ6+)Q4+T-E.ZZ*7Z;2N+CN]+;N?F-U7/O=\:HN, M<*";AND!HI2(PXFROZ/O$F= A,&PR>>F, %\:ZP9U!XRTM $-BO54GF[3$]) M+WJI&>!TA[D.%V0'/R/G&06?A'F"L%O 2;AL9OINC<#"SEO6_3G+>B7=W%;@ M Z>;V-9Y]Z]^__/P7;G\(!,;))K0G(J:#M!'T-?0Z60"!#,[S00GB(G;8K#M M'RC7#*(J>P1Q;,WR\])[&-J)>7$JA>(4!,L=-C0]3#(*3$JD2Y/WT>F^=UM_ MG#/UD1MV&JZXL #D9$$ZXS!>FYI&FPT$Y9/9S!0GJK]7& 3_EG&0+FI%+!".&P;1QT*/.H70^HX0SJA&^A;5;H@")'F.9>K/L,7/ MJVXUH;IM6YOI1E> _6T&&?&FHR_1Y'=4*8OBV;Y0!X_=%_#0 I,V@KGPOZRR00A]896>59)3\+^LE(3TW6?F3TV+ 5_[C*<+ M!KODC(KN\/#NYJ=,_ Q/?)'+F%I4+?3MBUMFA]H%]*?W48B]!&E_Y?8C(*[E2J;1?QL3,2DL/_^./,==/NP0[ MTHIA>.5 6,7)5XBJ/-V4<5?@*2 YL)F;<=.WN\DR_<0,:SJCD>EA!0-!LT " MZ?@W,SF4GJ$+EP\KNIZE"0'E3]YSR_?X67M["N*?;C!4QV M,V&R&[K.F>>%/\Y-FRGIYOK@[X]_.J?-BR]O?\YH_.P$&$)UV;H MXCP[S-9/.6.&8^G/S*T%Z=I/8Y+CL+@IL1 MS&*NX=B,V#*4V<-8S_+1JR64,RJ7*/4(1PUM#NZ&#>BYW,H4KRJ5*W]TY4^T M1UJ9.(ZX75&R]8.2^LS.7&Y9VN+< 36Z0F;^*%/QWOGS_)NAW52^/=89F<<3 MYXB:K>\KY9Q:*2W4 J9MK!LOLD^K8E]]#Z+4R3H);AI,N\G@*35U7>[ QH I MEKXS)GUF.7?$#(ZP3QT^(H>Y]V1@6JAKI@>*)YBM,QTL,/',D6\):C/']ZP) M\2",]@83.3(1&T#B":=.QR'&6X3$Q@>V?$8 M(^^8S3CL6VT;QOK!D7LCK^8#/ M[K-M*7Y.R-?JP5H9&](,+-,25I/P8)5DC_V;4@>D/R)NJPU05E#+-*>I,&R0=B5JN MJ3Z4B_F@]U8E-DLE(K?WBC,TV7CM0Q:PHA/#+P>#90[P.:U6^TJC^.?5^K>0 MY;3$563_A54$J,QI,3*7[1XQ==%SZDY_5](RVT)^H#!!_ZW*;);**.DJT_8\ MG_%[%6>_=\8FVIE_<&H\M>(L4!17G\JK4Y\2RY5WM-75)^S_;*FI9PJ&-N60 M=>;Z9H*@E7$(>^/+-BW^1BL6!;&P3-MP] G#T>CXHD^UFR%W0%$0B,-KY,XP M!=O 8L(>WER/TO*,:@;1+.IYV\*K^_C&*0J;I*L[&?4=:\?;W7+M'JYAA7=" MV%BT@8"E A71C-FY]5XN21">]Y-'%GY"!;1\?%L0-A%HYVLT=-'%;F;=LR[D2=WRV+ T* $MB1="K[H'XI77/WC8&0]4@P22.(R< @R M<-:YW"[M.I?V[9R.1][R\CLU9??;%[?7_=ZY>MB=FOE*?#2KBT7X:73$A:": MK??"1-+%EVZ+-"1BF-+Y>7,%R?B7N_=/3G#;UC% 8YG^A&AX1H:X;V#;9++T M>.X R_0(X(7H#LD;$M@<[X2!<9Z+AUK4(SH;F'9PG2C(K1?W4VZ'SBZ%EL@. MLNS@2.;7B_L9V=F4%Y%AY3BBX0ZY;H7'/?KR[(KI1TZS:[$[5M^084:214:]Z;D!K>ET_7G M[5^'U>]G[L10'_8LQBH9RV64Q+5'63E3N?G"^%S:$T"./>]V18?L"(9_\S'A M"ECD(VW288T]N!; S8&C6B,55T2(IN%Z1?J8L_Q7/-\UGP]+!OR+B:RYA->B M*_O#?']RXA8;R!'+T@QOY],,47T&%FA$:X+^X\,AE']=XM,GWM8+V'Y$\&&8 M&FEPVC>UZ+D]7)H+!]&2,X8/>;(70Y?F7J<5"P^ M3!47>#2#\3L2=&7,\\"% \<&_$!JV^"XH?[(WA:%#X:\=BO M;YPPXE((9I?'G>#3#3D=$>D2X@C#Y+(D=$!.>)YT3N]Z07G._"8,Y[?_PI0 M@@D"MTW84*T @ 1)@9X RQZ0Q$/B)+WQ.IA]1][)6Y"MN=]_Z= MM_IR.^_I-/R6]QS1/GO2,(;&U'N9+7BSZCTVN19E1]_-)* MK7Z(5G3MJ8-_ M1-%).M=^NAKEH44G:U;OR"6Z8]FS2QX,/^ MCEHL[ZFEPSUU?W_W2:HOT8-]\;5Z8I?IF)+@D?YA\;"LE)5K-JY6$"-9 M(AG>5^Z$008XF;/G",FRYPCWB"[=V&04 [)/U[3\GY*59&ODAU(L_].7O.D MEV72C[0Q54@UO&@NB3BA@@9/$NVP49_IF/+'N X#1P.[XU_?(?CG=X@>/G/Z MBE_D^0?3=F_Z7=VFW[?I]W]2^GW#%7)C:7N&BM=N^]U%H_>QT^ING[1^TIT] M_O!]4#SPS3=YF$Y8K19I+ZWJ0/>M"=&HCY4",IT;/,N.R<\^(QY,!QJ>8=SHVQA/=3,-'[6OS3GX MJ3XM$(K?OLFJ:[8J6*O[X;+9.C\GO;-6IW'5^MAK-[ND>=FYNNPT>OBW<-;T M?FJX%)7UYOU>Z#KCLI_1ODC)F! F4/]9?C'_NX@K%TG-]Y.:IN1 MCREX!7+*,=<GI_1YY#Z5&FH;)!K = M1V^^7TC;+L\WR;+,\JRMD ?]H MM/QSY&)DU?\/4$L#!!0 ( !E(=5@8(!X>P0T (,P 2 9S X-#$T M,5]E>#DY+3$N:'1M[5MK;]M&%OTN0/]AUMAD4T"27WG:CK'RJW'7<0Q;[:*? M%B-R)$U,^_=X/W9?KNU M]^ZX?X3OC/[M#4X'9\?[>^O^.^ZNA]M[!Q^.?F97@Y_/CM^NC51A=]CF1FG9 M0.;"L',Q8Y&)W6<[U6.+C MQMK^WLF'\T'SB.Z(YS*;[]Q_R"YSSQKYJ_ RK>T_+8:FW-U;IPWW]P[VCS]- MY%#:=NO-F][FWOH!%+RX(5HMQRZ[)>4:[1'W7+78VV.HLI1M;<$H?2UYUF'O M1#855B8]XW9;-F8C""DWVO"1,/9K6AQ.M8YXT7*WDDM MBS$]>*1[[$KFJF"'$]S)A'Z(P3:??[GK[S#/(\)A'P^W6U'/ 000UK!C8X$/ M*U+VSZW>"W8@LTQ"W=I"[[F^%G9O_73_,YIO?AG>Z?%EG3]6$&4T?TRE3[00 M$WBDTV[1HA^$-F+.GN8I-Y-=4@UPV-KLL*V-K>?UY0:$!A.A>2DJJ&+8H=)E MCSU[FJ6_5&IW\=13[2YTF-+,3@2+#ZB\Y,4\W/VNPYZ=_WQUW&[UY9=*R"3>P#$5 -F>9BP&1MEL2SA?P\HT]RX"/F;03)\WDGF#H?8.8 M@$_;K> <-A29A+4-(VL8E-2P"1 P%,Y6T?)@),BK, MS;C6L#OL4UM3%BGTM/"JZ0$V.9F,)Y45*Q^!*XHDJU+!$J4+ :+"Q@+J@TS2 M.4LYT3>!BP\U-UC1"9OQ8@PIDDR92@LVAFL36, Q6*D,M*Y@V@3[&?%+)3(N M>@[;A4P^(P>OK))Y7A7 HC2"&[)GJN=N&6U?B$JKDML);87%F1I+87JL&12& M8&]8F7%+Z&-5(4F*.;.!>0A()3>$!Z&,@2*%D;A%HO>02PP1D/C$\Y)4@4]$2.?!/D@0 MPGE8JVH\@7]?$#Y+VV'MF;CHV50[NU M0A58()[I"HNA/_9;C,_3=FLF,G"K<"DP)C\'FDRI:P+'C.N4V&FF]#79QS'7 M1**>- RF'%?P&E$>?!@CV"I:Y#Y/94J+\@HA@DH@%6EG%1S;K1""=)*I\(!& M17,C]=QVG1-TG*DA.;?&+K%JBI.^18_ #U#.)$L$ M:W>\1RCZV/8&FPL>#/>IQ!D"!1.9SJUSU4XY00!E1$BIKL9+)5FDM![,T6Y1 M=<79Q:1W1!L<6%)T5M04 M-1?2UA."^5&E0>+<9XWOF]7( 9B0:E/L[T!*UV0QRGB>NR3DMF9(2&#;Q#(Z M0^CY+6#^H]ME)U)DZ0Y:D['8!3Q04ZLQ M?>DZHT'_X.P8M'UV=M$_.CH]__[MVL::^WQUT3^,G\.60Z6)FA.59;PT.#K^ MM N$I79"$-UXLJH!&US&/6!S"J(L1@CD6PZ93(S7+--!*91 MF4SKH[>WGRP:^\'1U^SP_,D=G6C#^M'NNVPP+Z%@'_E()KM(PKGPOCE7Y)#F MFO6XR-WX2N&VGZP9$Z6)Y]Z:F9 "/QT=A MT[5[J7E]<^/5DR_8\?7O0,][!_O]H:HLA4[MU2RDPO&,T M25DAR63AXART"$@,I;(H8 M'ZN -WX*.5%*%\CGPLJ^O4GHB%SJ!\O)7NE8@ M>\$.BWF _QE97+I"P17*"W&0!Y'P!>I<*Q:\J^@9T+51B71CGURDCM!16J8R M]*R#1==0-W)0Q4IZ+BCE!2=%J1@1F2]6LCFD<%6Y2R6A'L>NW5"3L^M"S0K* M%Z%DCUU*H\\8U?V!!;^X5!3;@F;G6>L4<]%*P=LM*DI'(!*RAU$L=+E4>(EN MK0T5;N0#;Y_E/@*E;R)*9&^DIJ$3R6?$1G.%79&34V<,U!09*OU0RM=&;[?( MY:JBIU8J38XD!U"-<&N,<((5$3)5F=9U'<[+4,R@=J$C.85=H_7HH,U!M<%F MLUDO630D"75GFC)UEJD9VBS2W"$BX9*G/7/;HBF&QL MOE'"&:!K (I=XZP1:.BV*5HM,&)B[]'-O+JH)*.V>':,.W31KHCGT/.["CBQ M?!'Y1MRS:3TD\@4UH2V3N?3KJ4>DGL0-W6E4L^+8YG$-"9_)[U8^[F8,HSC+ M1,S&6$8O-%H:@'[=?*Z#DQ]P])W]>KOUD%;=12H.6C[I7\:SAFV21H+:D&3\ M#%?<(@B7B^"ZAO^I[R^41?.)NAH'>28=59;&A6A[W%"8*C*2CAX&NWV$&M9%8J@J6W/UEM*)QQZQZ2 M[)]*DU [C3N=SU4NC01W_-3ZVM-?8W"HFEMGDPD2C;*6R#'"D!4&E=+ M&A)QHK=1J"SJ ^'NAO4](SJ3Q*#TA4$ZY>ZM$!YO3)90WZSBODY $% &O*93 M>F]&PKF%*\ER!&,5KGZHZTBRSG0UM3;LJH8VEG$Y!:#[D*)7)%O_V+OJN5OA MC0BR(+=A!F-)!UB4\!XM&H"UPA^$D[$OS2DKI#G*/F.I6)^Z $H\\L#Z4)/F M=""5DFL:9-+(R,')'8WMJ2H<"Y<*O80^ZMPKFR!?QF<^;!%TH$&?[WQ (NQ2 MZ8Z?Q-0,SX(Q<&/IF!M!NC.%^[Y6(%473M"2XVA08=3$E@\/'S] M_.5S4FO=N:"F!%0T:8/N9#$B4A$-:_A&/W@6-8>;Q4(_C]*9RRA#L:!Q3[(^ MTTSXE-@X9A06X!RB(+ZUB$SHBXK;M0"]B"T"*Q9JD6 7Q4)(:2BQ M*7V5Z&;THG-RTS3T%/$S3?_($[&"B6P_%7?)T\ &2X35M2[A'*AD52': U] MG(FT?B42RC_"KJ\(XGIGNBB:)9OY:]#\CDJI(0UA'2=<"^1*R*7F(NQH$DG0 M!"4Z1I&&F"\T,-Q:&OQUXFI'!@KZ$P> "3(L@^0H68RB?BR6J8M^]JY4[HH2 M81(MAU2=$1/Z$:@,+QI-8!%D$_J.A\*[FDOL& N7.#*7*\F278IQX!)L5'<; MA"SZQ1-VU=UDSZZ.#]F)1(8^5SVVO;W=W7KY9O/UZ^]0MYW<7<.$*C]Z39KZ M];X[P;$[13[DY=D6KY-4P"O*:5=Y;O(UTE163FZD&GA/A$_2YM MJ\'$$G6'L[/"A \(_@>H_<$.M0=\8GOYUM'[YZG7WQ:N-[LM7;S;_.EH[7__[<&D: M]V#M:>3V&6%^[YG;@RGJ"^9J6R][6X_\^["KQ;SGG>+VW^\4_WZG^"=\I_@; MQ-:-J+KC%^H;+S+7Z8\(_%\5T!\?_!]02P$"% ,4 " 92'58\TZUTRL# M #I"P $0 @ $ 8VAR;RTR,#(T,#,R,2YX&UL4$L! A0#% @ &4AU6$,YNB57!P V5< M !4 ( !B@X &-HP0T (,P 2 M " <,G !G,#@T,30Q7V5X.3DM,2YH=&U02P4& 4 !0!! 0 &M#4 end XML 18 g084141_8k_htm.xml IDEA: XBRL DOCUMENT 0001919246 2024-03-21 2024-03-21 iso4217:USD shares iso4217:USD shares false 0001919246 8-K 2024-03-21 Chromocell Therapeutics Corporation DE 001-41964 86-3335449 4400 Route 9 South Suite 1000 Freehold NJ 07728 732 514-2636 false false false false Common Stock, par value $0.0001 per share CHRO NYSEAMER true false